CliffBio
biologic

NUVAXOVID

COVID-19 Vaccine, Adjuvanted

Loss of exclusivityMay 2037projected — 12-year biologic exclusivity estimate
CompanySanofi Vaccines US Inc.

Drug detail

Brand nameNUVAXOVID
Active ingredientCOVID-19 Vaccine, Adjuvanted
Strength5UG
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalMay 2025
Marketing statusRx

More from Sanofi Vaccines US Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

NUVAXOVID patent cliff — loss of exclusivity May 2037 | CliffBio